Stereotactic radiosurgery for glial neoplasms of childhood

WE EVALUATED THE role of stereotactic radiosurgery (SRS) in 25 children with surgically incurable brain tumors of glial origin. Histological diagnoses were obtained at the time of craniotomy and attempted removal (n = 20) or by stereotactic biopsy (n = 5). Thirteen children had tumors with benign histological characteristics (pilocytic and low-grade astrocytomas), whereas 12 children had tumors with malignant characteristics (malignant astrocytomas and ependymomas). Eleven (10 with malignant tumors) of the 25 children had received fractionated irradiation before SRS. Radiosurgical doses (range to margin, 11-20 Gy) were calculated on the basis of tumor volume and location, with consideration given to prior radiation dose. Follow-up for the 13 children with benign tumors ranged from 6 to 48 months (median, 21 mo). Eleven of the 13 children with ''benign'' glial neoplasms had tumor control with SRS alone (no evidence of tumor, n = 4; decreased tumor, n = 5; and unchanged tumor, n = 2), and all 13 remain alive. Five children with malignant tumors are alive at 12, 45, 50, 72, and 72 months after radiosurgery. The other seven children with malignant tumors are dead, with a median survival of 6 months after radiosurgery. Three of 12 children with malignant glial neoplasms had tumor control after SRS. Two of these three children received fractionated irradiation as an adjunct to SRS. Complications occurring in four children were transient, associated with peritumoral edema, and responsive to oral glucocorticoids. There was no relationship between tumor volume and local control after radiosurgery. Radiosurgery alone is a safe and effective treatment modality for unresectable benign gliomas of childhood. Radiosurgery may have a role in the adjuvant management of unresectable malignant glial neoplasms of childhood if other therapies (irradiation or chemotherapy) are available.